Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications

Microvascular Research

Volumn 95, Issue 1, 2014, Pages 1-6

  Chawla, Diwesh ^a   Bansal, Savita ^a   Banerjee, Basu Dev ^a   Madhu, Sri Venkata ^a   Kalra, Om Prakash ^a   Tripathi, Ashok Kumar ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Advanced glycation end products; Oxidative stress; RAGE expression; Type 2 diabetes mellitus; Vascular complication

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MACROVASCULAR DISEASE; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAGE GENE; REAL TIME POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; VASCULAR DISEASE; WESTERN BLOTTING; ADULT; BLOOD; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GENETICS; MIDDLE AGED; MONONUCLEAR CELL; PROTEIN CARBONYLATION; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; UP-REGULATION;

EID: 84922256979     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2014.06.010     Document Type: Article

References (30)

1. Aydemir B., Onaran I., Kiziler A.R., et al. Increased oxidative damage of sperm and seminal plasma in men with idiopathic infertility is higher in patients with glutathione S-transferase Mu-1 null genotype. Asian. J. Androl. 2007, 9:108-115.
2. Bansal S., Siddarth M., Chawla D., et al. Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. Mol. Cell. Biochem. 2012, 361:289-296.
3. Bansal S., Chawla D., Siddarth M., et al. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin. Biochem. 2012, 46:109-114.
4. Bansal S., Chawla D., Banerjee B.D., et al. Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients. Gene 2013, 526:325-330.
5. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002, 287:2570-2581.
6. Bo S., Ciccone G., Gancia R., et al. Mortality within the first 10years of the disease in type 2 diabetic patients. Nutr. Metab. Cardiovasc. Dis. 2006, 16:8-12.
7. Clynes R., Moser B., Yan S., et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr. Mol. Med. 2007, 7:743-751.
8. Daroux M., Prévost G., Maillard-Lefebvre H., et al. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 2010, 36:1-10.
9. Genuth S., Sun W., Cleary P., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
10. Girotti M.J., Khan N., McLellan B.A. Early measurement of systemic lipid peroxidation products in the plasma of major blunt trauma patients. J. Trauma 1991, 31:32-35.
11. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
12. Herold K., Moser B., Chen Y., et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 2007, 82:204-212.
13. Higashi Y., Noma K., Yoshizumi M., et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ. J. 2009, 73:411-418.
14. John W.G., Lamb E.J. The Maillard or browning reaction in diabetes. Eye 1993, 7:230-237.
15. Kalousová M., Skrha J., Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 2002, 51:597-604.
16. Kaneda H., Taguchi J., Ogasawara K., et al. Increased level of advanced oxidation protein products in patients with, coronary artery disease. Atherosclerosis 2002, 162:221-225.
17. Kerkeni M., Saïdi A., Bouzidi H., et al. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Vasc. Dis. Res. 2013, 10:239-245.
18. Kilhovd B.K., Juutilainen A., Lehto S., et al. Increased serum levels of advanced glycation end products predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18year follow-up study. Diabetologia 2007, 50:1409-1417.
19. Lander H.M., Tauras J.M., Ogiste J.S., et al. Activation of the receptor for advanced glycation endproducts triggers a MAP kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
20. Linden E., Cai W., He J.C., et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin. J. Am. Soc. Nephrol. 2008, 3:691-698.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
22. Nin J.W., Jorsal A., Ferreira I., et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes Care 2011, 34:442-447.
23. Pan H.Z., Zhang H., Chang D., et al. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br. J. Ophthalmol. 2008, 92:548-551.
24. Su X.D., Li S.S., Tian Y.Q., et al. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes. Arch. Med. Res. 2011, 42:596-601.
25. Tripathi A.K., Chawla D., Bansal S., et al. Association of RAGE gene polymorphism with vascular complications in Indian type 2 diabetes mellitus patients. Diabetes Res. Clin. Pract 2013, (2013 Dec 25. pii: S0168-8227(13)00437-3.). 10.1016/j.diabres.2013.12.004.
26. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001, 280:685-694.
27. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., et al. Advanced oxidation protein products as novel mediator of inflammation and monocyte activation in chronic renal failure. J. Immunol. 1998, 161:2524-2532.
28. Yamagishi S., Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxidative Med. Cell. Longev. 2010, 3:101-108.
29. Yan S.F., Ramasamy R., Schmidt A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:285-293.
30. Yoshida N., Okumura K., Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005, 54:345-350.